对于中度至重度斑块性牛皮患者的 efalizumab:一个随机对照试验
Kenneth B Gordon1, Kim A Papp, Tiffani K Hamilton
1Loyola University Medical Center, Maywood, Ill 60153, USA. kgordon@lumc.edu
JAMA
|December 18, 2003
概括
在12周的试验中,Efalizumab显著改善了牛皮的严重程度和生活质量. 这种T细胞调节器在中度至重度斑块牛皮患者中显示出安全性和有效性.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 临床试验 临床试验
- 牛皮病理生理病理学
背景情况:
- T细胞相互作用是牛皮发育的核心.
- 准T细胞为牛皮提供了潜在的治疗策略.
研究的目的:
- 评估T细胞调节剂efalizumab的疗效和安全性.
- 评估 efalizumab 对斑块性牛皮病严重程度和生活质量的影响.
主要方法:
- 第三阶段,随机,双盲,安慰剂对照试验.
- 556名成年患者中度至重度的斑块性牛皮.
- 每周12次以皮下注射 efalizumab (1 mg/kg) 或安慰剂.
主要成果:
- 埃法利祖马布组获得显著更高的PASI-75响应 (27%与4%,P<.001).
- 随着 efalizumab (P<.001) 的使用,DLQI,VAS和PSA的更大改善被观察到.
- 伊法利祖马布是安全的,耐受性良好,并有轻度至中度的不良反应.
结论:
- 埃法利祖马布在12周内在斑块性牛皮症中显示出显著的临床改善.
- T细胞调节器改善了医生评估和患者报告的结果.
- 伊法利祖马布为中度至重度的斑块性牛皮提供了安全有效的治疗选择.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880


